United States · Platforms & data · MarketBeat

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Published by MarketBeat · United States 53 min ago

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

An OpenAI Model Spent Ethereum Without Permission. Here's What That Means For Crypto Investors.

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Investing.com

Ukraine says Starshield back to normal, Musk says Kyiv violated terms

Benzinga

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Yahoo Finance

Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?

Stocktwits